Transarterial Treatment of Lung Cancer

• Published in: Life (Basel, Switzerland) Vol. 12; no. 7; p. 1078
• Main Authors: Hori, Atsushi, Dejima, Ikuo, Hori, Shinichi, Oka, Shuto, Nakamura, Tatsuya, Ueda, Shota
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.07.2022; MDPI
• Subjects: antineoplastic agents; Arteries; bronchial artery; Cancer therapies; Catheters; Chemotherapy; Complications; Coronary vessels; Disease; Disease control; Drug dosages; embolic material; Embolization; Lung cancer; Lymph nodes; Lymphatic system; Medical prognosis; Metastases; Metastasis; microcatheter; Mortality; Pulmonary arteries; Radiation therapy; Remission; Squamous cell carcinoma; Survival; Tumors; Veins & arteries; United States > US; Japan
• DOI: 10.3390/life12071078
• ISSN: 2075-1729

Purpose: The treatment efficacy of the transarterial approach to lung cancer is evaluated. Materials and Methods: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from the subclavian artery were selected by a microcatheter. Immediately after the selective arterial infusion of anti-neoplastic agents, embolization with a spherical embolic material was carried out. Local tumor effects and overall survival were evaluated. Result: The mean reduction rate was 17.9%, with 24.2% for partial remission and with 2.1% for progression disease. The rate of stable disease was 72.6%. The response rate was 25.3%, and the disease control rate was 97.9%. The median survival time (MST) was 11.4 months, the 1-year survival rate was 45.2%, and the 2-year survival rate was 35.6%. Although it is insignificant, the MST for 51 adenocarcinomas was higher than that of 29 squamous cell carcinomas (18.6 months and 9.4 months, respectively). The local extension of tumors related to a better prognosis, though it was not significant. Lymph node metastases and distant metastases were poor prognostic factors. No major complications nor treatment-related mortalities were found in this study. Conclusion: The transarterial treatment for lung cancer should be considered as a treatment option when the other treatments were not indicated both in initial cases and in recurrent cases.